Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828377/

In the Asian population, 50-60% of non-small cell lung cancer (NSCLC) patients carry the epidermal growth factor receptor ( EGFR) mutation. Although treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) is effective,...

Cyclin D1 expression in KRAS mutant non-small cell lung cancer-old wine into new skins

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815367/

Globally, lung cancer has the highest mortality rate among all cancers ( 1, 2). Non-small cell lung cancer (NSCLC) comprises >80% of cases ( 3). Oncogene driver mutations in EGFR,...

Sensitive Detection of KRAS Mutations by Clustered Regularly Interspaced Short Palindromic Repeats

Source : https://www.mdpi.com/2075-4418/11/1/125/htm

Kirsten rat sarcoma viral oncogene (KRAS) is the isoform most frequently mutated in human tumors. Testing for activating KRAS mutations has important implications for diagnosis and the personalized medicine of...

Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type

Source : https://www.nejm.org/doi/full/10.1056/NEJMc2030638

Our apologies. An error occurred while setting your user cookie. Please set your browser to accept cookies to continue. NEJM.org uses cookies to improve performance by remembering your session ID...

MEK inhibitors for the treatment of non-small cell lung cancer

Source : https://link.springer.com/article/10.1186/s13045-020-01025-7

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They...